Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Beginning Cash Balance: 2017-2024

Historic Beginning Cash Balance for Kiniksa Pharmaceuticals International (KNSA) over the last 8 years, with Dec 2024 value amounting to $108.0 million.

  • Kiniksa Pharmaceuticals International's Beginning Cash Balance rose 63.63% to $369.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $274.6 million, marking a year-over-year increase of 12.44%. This contributed to the annual value of $108.0 million for FY2024, which is 12.03% down from last year.
  • Per Kiniksa Pharmaceuticals International's latest filing, its Beginning Cash Balance stood at $108.0 million for FY2024, which was down 12.03% from $122.7 million recorded in FY2023.
  • Kiniksa Pharmaceuticals International's 5-year Beginning Cash Balance high stood at $122.7 million for FY2023, and its period low was -$67.1 million during FY2020.
  • For the 3-year period, Kiniksa Pharmaceuticals International's Beginning Cash Balance averaged around $117.7 million, with its median value being $122.5 million (2022).
  • Per our database at Business Quant, Kiniksa Pharmaceuticals International's Beginning Cash Balance tumbled by 367.93% in 2020 and then spiked by 270.24% in 2021.
  • Kiniksa Pharmaceuticals International's Beginning Cash Balance (Yearly) stood at -$67.1 million in 2020, then surged by 270.24% to $114.2 million in 2021, then climbed by 7.20% to $122.5 million in 2022, then rose by 0.20% to $122.7 million in 2023, then declined by 12.03% to $108.0 million in 2024.